English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Bisphosphonate-related osteonecrosis of the jaw (BRONJ) is side-effects of Bisphosphonates (BP) used to prevent and treat osteoporosis, to treat Paget’s disease, multiple myeloma, bone metastases, and associated malignant hypercalcemia. Nowadays the American Association of Oral and Maxillofacial Surgeons is renamed BRONJ intoMRONJ (medication-related osteonecrosis of the jaw) according to due to reports of several non-bisphosphonate drugs resulting in the loss of alveolar bone and clinically appearing similar to BRONJ. Those terms can be used as synonyms but BRONJ is more detailing the pharmaceutical etiology of the specific case of osteonecrosis. BRONJ is currently diagnosed on the basis of necrotic bone exposedin the oral cavity for at least 8 weeks in patients with no history of head or neck radiotherapy.

journal of diagnostics and treatment of oral and maxillofacial pathology

Review of ‘‘A Case of Bisphosphonate-Related Osteonecrosis of the Jaw With a Particularly Unfavourable Course: A Case Report’’ by Viviano M, Addamo A, Cocca S in Journal of the Korean Association of Oral and Maxillofacial Surgeons 2017;43:272–5